Business
Therma Bright Major Milestone: Portfolio Company Inretio's Preva(R) Device Achieves 3rd Human Trial Success
Game-Changing Innovation Poised to Transform Stroke and Blood Clot Treatment Therma Bright's S...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright Major Milestone: Portfolio Company Inretio's Preva(R) Device Achieves 3rd Human Trial SuccessGame-Changing Innovation Poised to Transform Stroke and Blood Clot TreatmentTherma Bright's Strategic Investment Helps Medical Device Company Demonstrate Efficacy and Safety in Transforming Ischemic Stroke CareToronto, Ontario--(Newsfile Corp. - August 27, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) (\"Therma\" or the \"Company\"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is thrilled to announce a groundbreaking achievement by its investment portfolio company, Inretio. Inretio's Preva® ischemic stroke clot removal device has successfully completed its third (3rd) human trial, as announced by the device company via their LinkedIn page.The Preva® device represents a significant leap forward in thrombectomy procedures, offering unparalleled precision and efficacy in blood clot removal. This cutting-edge technology is uniquely designed to safely and effectively restore blood flow in patients suffering from Ischemic strokes, even when traditional treatments, like tPA, fall short, which was noted by Dr. Gal Yaniv on his LinkedIn post around the third (3rd) patient's Preva® success. Dr. Yaniv serves as Director, Endovascular Neurosurgery unit at Sheba, Tel HaShomer City of Health, Aidoc CMO. The unique patented solution offers a new approach to clot retrieving by reaching distally to the clot and opening the patented protective basket, as a result, potentially minimizing the risk of embolization and reducing the need for repeated maneuvers in the procedure.Mechanical Thrombectomy is a minimally invasive procedure involving the removal of a thrombus (blood clot) from an artery in the brain. The procedure is effective for patients that won't comply with drug treatment. The result of mechanical thrombectomy will impact the patient's life and long-term disability.As reported in a prior release, iDataResearch projects the global coronary stents market size will \"reach a value of more than USD $4.8 billion in 2029.\" With Inretio's Preva® solution, this present a nice growth opportunity for the business and Therma Bright's investment in this innovative device.\"We are incredibly proud of Inretio's remarkable prog...